

Attorney Docket No. 5702.240-US
Jeppesen et al.
Express Mail Label No. EV 246879475 US

Attorney Docket No.: 5702.240-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jeppesen et al.

Application No.: To Be Assigned

Group Art Unit: To Be Assigned

Filed: April 13, 2001

Examiner: To Be Assigned

For: New Compounds, Their Preparation And Use

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. Copies of references were either submitted to, or cited by, the Patent Office in parent application USSN 09/419,864 filed October 19, 1999, the benefit of which is claimed under 35 USC 120.

The references are as follows:


1. Abstract of Japanese Patent No. JP 10182550
2. WO 97/36579
3. WO 97/25042
4. WO 96/04261
5. WO 96/04260
6. WO 99/19313
7. Wilson et al., J. Med. Chem., 43, 2000, 527-550.

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed on filing date of application. Therefore, no fee is due.

Date: January 6, 2004

Respectfully submitted,


Rosemarie R. Wilk-Orescan, Reg. No. 45,220
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application

23650

PATENT TRADEMARK OFFICE

FORM PTO-1449
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEAtty. Docket No. **5702.240-US**Serial No. **To Be Assigned**INFORMATION DISCLOSURE
STATEMENT BY APPLICANTApplicant **Jeppesen et al.**

(Use several sheets if necessary)

Filing Date **January 6, 2004**Group **To BeAssigned**

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		WO 97/36579	10/09/97	WIPO				
		WO 97/25042	07/17/97	WIPO				
		WO 96/04261	02/15/96	WIPO				
		WO 96/04260	02/15/96	WIPO				
		WO 99/19313	04/22/99	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

			Abstract of Japanese Patent No. JP 10182550
			Wilson et al., J. Med. Chem., 43, 2000, 527-550

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.